Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Two passengers travelling in Singapore airlines arrived in New Zealand with measles symptoms. However, reported The Strait Times, that they are not linked to any other known cases, as noted by the Communicable Disease Agency (CDA).

The agency told the media outlet that it was notified on February 25 that two Singapore Airlines (SIA) passengers infected with measles landed in Auckland, New Zealand. Both were from the same household and flown from Hyderabad, India. They transited in Singapore for two hours before boarding an SIA flight to Auckland.

CDA investigation also revealed that these two cases remained in the transit area at Changi Airport. Associate Professor Lim Poh Lian, group director of the CDA's Communicable Disease Programmes, as reported by The Strait Times noted that the individuals were reported to have developed symptoms only while onboard the flight from Singapore to Auckland.

New Zealand media earlier reported that the two cases were detected after the individuals arrived in Auckland on flight SQ281 on February 17. The country’s public health authority began tracing passengers seated in rows 31 to 46 on the same flight, along with people who were present in the waiting area of Waitakere Hospital’s Emergency Department on February 21.

“Based on the onset of their symptoms, they were infected before transiting through Singapore and are not linked to any other known measles cases in Singapore,” Prof Lim said.

She also clarified that their time in transit through Singapore did not coincide with that of a previously reported measles case involving a passenger who had passed through Singapore en route to Los Angeles in the United States.

What Is Measles?

Measles has a high transmissibility, and high measles immunity levels are required to prevent sustained measles virus transmission.

This is why herd immunity for measles could be easily breached.

It easily spreads from one infected person to another through breathes, coughs or sneezes and could cause severe disease, complications, and even death.

Symptoms include:

• High fever
• Cough
• Runny Nose
• Rash all over the body

The most unique symptom or the early sign of measles in the Koplik spots. These are tiny white dots that look like grains of salt on red gums inside the cheeks that appear before the red rash starts to appear on a person's face and then the body.

Furthermore, the symptoms of measles are also characterized by the three Cs:

• Cough
• Coryza or runny nose
• Conjunctivitis or red and water eyes

Update On The Passengers Who Landed In New Zealand

The passenger on flight SQ38 arrived at Los Angeles International Airport at about 7pm on February 9, after a roughly two-and-a-half-hour transit at Changi Airport following a flight from Cambodia.

Prof Lim said the most effective protection against measles is to be fully vaccinated before travelling. She also advised travellers to practise good hygiene, such as washing hands regularly and avoiding close contact with anyone who is unwell.

Anyone who develops symptoms like fever, rash, cough, red or watery eyes, or a runny nose should wear a mask, seek medical care promptly, and inform their doctor about their recent travel and any possible exposure to measles, she added.

In response to queries, Singapore Airlines told The Straits Times that it is working closely with the authorities but cannot share specific details due to customer confidentiality.

In a major push towards eliminating cervical cancer from India, Prime Minister Narendra Modi today launched the nationwide Human Papillomavirus (HPV) vaccination program for girls aged 14 years.

The new vaccination drive comes as cervical cancer remains the second most common cancer among women in India, with nearly 80,000 new cases and over 42,000 deaths reported annually. As per data from the ICMR-National Cancer Registry Program (NCRP), an estimated 78,499 new cases and 42,392 deaths were reported in 2024.

Calling it a "decisive step”, the government noted that it is aimed at “strengthening the vision of ‘swasth nari’ (healthy women) while being rooted in scientific evidence, strict regulatory oversight and global best practices”.

“India's vaccination drive reflects safety, responsibility, and long-term commitment to women’s health,” it added.

The national program will use Gardasil, a quadrivalent HPV vaccine that protects against HPV types 16 and 18, which cause cervical cancer, as well as types 6 and 11.

However, social media has been rife with concerns around the safety of the vaccine, its impact on women’s reproductive health, among others.

HPV Vaccine: The Myths And Facts

Myth: HPV vaccines can cause severe side effects and even death.

Fact: The HPV vaccines come with a “confirmed strong safety record”.

“Extensive global monitoring shows a strong safety profile supported by scientific reviews. Independent evaluations have found no causal link between vaccination and chronic harm, strengthening confidence in its continued use worldwide,” the government said.

The vaccine has been licensed in India since 2008, and the new rollout follows recommendations by the World Health Organization (WHO) and approvals from the National Technical Advisory Group on Immunization (NTAGI).

“HPV vaccines have been given to hundreds of millions globally. Extensive post-marketing surveillance shows an excellent safety profile, with no causal link to serious adverse outcomes. The evidence is robust, transparent, and reassuring,” Dr. CS Pramesh, Director of the Tata Memorial Hospital, Mumbai, shared in a post on the social media platform X.

Myth: The HPV vaccine has never been used in India

Fact: The vaccine has been in use in India. It has been administered for years since 2008 with successful implementation in states like Punjab, Sikkim, and Tamil Nadu.

Myth: HPV vaccination does not prevent cervical cancer

Fact: The HPV vaccine has been proven to prevent cervical cancer

Studies show a 65 percent drop in cervical cancer cases among US women between 2012 and 2019 and an 88-89 percent reduction in precancerous lesions among Scottish women over a decade.

Countries with early HPV vaccine adoption have also shown large declines in HPV infection, high-grade cervical lesions, and cervical cancer incidence.

"Even when considering the rarest side effects, HPV vaccines are overwhelmingly safe. The protection they offer against cervical cancer far outweighs the minimal risks. Parents are encouraged to vaccinate their daughters on time," said Dr. Neena Malhotra, Professor and Head of Department, Department of Obstetrics and Gynecology, AIIMS New Delhi on X.

Myths: Are Multiple Doses Needed?

Fact: A single dose of the quadrivalent HPV vaccine is effective. It provides strong protection against HPV infection. It helps prevent cervical cancer.

“Strong global and Indian scientific evidence confirms that a single dose provides robust and durable protection when administered to girls in the recommended age group," the government said.

Prime Minister Narendra Modi today launched the nationwide Human Papillomavirus (HPV) vaccination campaign for girls aged 14 years from Rajasthan's Ajmer.

The initiative marks a decisive step towards eliminating cervical cancer through timely HPV vaccination. Cervical cancer remains the second most common cancer among women in India. Nearly 80,000 new cases and over 42,000 deaths are reported annually in the country.

"Today, I have had the opportunity to launch the HPV vaccine campaign from Ajmer. This campaign is an important step towards empowering women and daughters of this country,” PM Modi said.

“For us, this was a sensitive issue tied to the insult of our sisters and daughters, one that made them ill. That is why we resolved it at a crucial turning point in their mission,” he added.

The World Health Organization has also lauded India's mission to launch the HPV vaccine and prevent the risk of cervical cancer.

“We are leaving no stone unturned to ensure that the daughters of the country are healthy and prosperous. The objective of this initiative is the prevention of cervical cancer," the Prime Minister, earlier wrote in a post on social media platform X.

The HPV Vaccination Campaign

The nationwide program, based on expert recommendations of the National Technical Advisory Group on Immunization (NTAGI), will target girls aged 14 years.

At 14, the HPV vaccine offers maximum preventive benefit, well before potential exposure to the virus.

"By prioritizing prevention at the right age, the program is expected to provide lifelong protection and significantly reduce the future burden of cervical cancer in the country," the government said.

“The HPV vaccine works best at 9-14 years, before exposure, and when the immune response is strongest. Studies show effectiveness is highest in younger age groups and decreases with age,” Dr. Parmod Kumar, Associate Professor in Medical Oncology, AIIMS Jodhpur, shared on X.

Vaccination under the national program will be voluntary and free of cost.

The HPV vaccination will be conducted exclusively at designated government health facilities, including Ayushman Arogya Mandirs (Primary Health Centers), Community Health Centers, Sub-District and District Hospitals, and Government Medical Colleges.

Cervical Cancer Burden In South East Asia

Despite being preventable, cervical cancer continues to claim the life of a woman every two minutes globally, and the WHO South-East Asia Region bears nearly one-quarter of the global burden.

Dr. Catharina Boehme, Officer-in-Charge, WHO South-East Asia, stated that the introduction of HPV vaccination at a national scale in India "will have a far-reaching impact". It will accelerate progress not only for the country, but for the region and the world, she said.

“This landmark step, led at the highest level of government, reflects India’s strong commitment to protecting adolescent girls from cervical cancer," said Dr. Boehme.

With today’s milestone, nine of the 10 countries in the Region now include HPV vaccination in their national immunization programs.

The WHO global targets for 2030 include vaccinating 90 percent of girls by age 15, screening 70 percent of women by ages 35 and 45, and ensuring 90 percent of women with pre-cancer and invasive cancer receive appropriate treatment.